The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine whether low baseline diastolic blood pressure (DBP) modifies the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: The Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP), a two-by-two factorial randomized controlled trial, examined effects of SBP (<120 vs. <140 mmHg) and glycemic (HbA1c <6% vs. 7.0–7.9% [<42 vs. 53–63 mmol/mol]) control on cardiovascular events in T2DM (N = 4,731). We examined whether effects of SBP control on cardiovascular composite were modified by baseline DBP and glycemic control. RESULTS: Intensive SBP lowering decreased the risk of the cardiovascular composite (hazard ratio [HR] 0.76 [95% CI 0.59–0.98]) in the standard glycemic arm but not in the intensive glycemic arm (HR 1.06 [95% CI 0.81–1.40]). Spline regression models relating the effects of the intervention on the cardiovascular composite across the range of baseline DBP did not show evidence of effect modification by low baseline DBP for the cardiovascular composite in the standard or intensive glycemic arms. The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction (P = 0.83). CONCLUSIONS: In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guideline-recommended standard glycemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, in ACCORD BP, it was found that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in patients who also received standard glycemic control (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“However, ACCORD BP demonstrated that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in individuals who also received standard glycemic management (51).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Self-citationProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Analyses of scaled Schoenfeld residuals (21) indicated no evidence of nonproportional hazards.”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 2×
“Statistical analyses and preparation of this manuscript were supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (R21-HL-145494), National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-091437), and the University of Utah Study Design and Biostatistics Center (funded in part…”
MethodMicrovascular and Macrovascular Complications of Diabetes
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.77 · Cited by 1,954
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Excess Mortality among Persons with Type 2 Diabetes
Tancredi, M., Rosengren, A., Svensson, A.-M., Kosiborod, M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Clements, M., Dahlqvist, S., & Lind, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504347 · Cited by 996
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.06.010 · Cited by 947
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.005 · Cited by 920
Self-citationMesserli, F. H., Mancia, G., Conti, C. R., Hewkin, A. C., Kupfer, S., Champion, A., Kolloch, R., Benetos, A., & Pepine, C. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-12-200606200-00005 · Cited by 779
BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE
Cruickshank, J., Thorp, J., & Zacharias, F. J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90231-5 · Cited by 656 · cited 1×
“Biological plausibility for the J-curve phenomenon has been proposed (6,24).”
BackgroundVidal-Petiot, E., Ford, I., Greenlaw, N., Ferrari, R., Fox, K. M., Tardif, J.-C., Tendera, M., Tavazzi, L., Bhatt, D. L., & Steg, P. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31326-5 · Cited by 470
Farnett, L. (1991) · JAMA · doi:10.1001/jama.265.4.489 · Cited by 417 · cited 1×
“Biological plausibility for the J-curve phenomenon has been proposed (6,24).”
BackgroundBangalore, S., Messerli, F. H., Wun, C.-C., Zuckerman, A. L., DeMicco, D., Kostis, J. B., LaRosa, J. C., & for the Treating to New Targets Steering Committee and Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq328 · Cited by 367
The Role of Diastolic Blood Pressure When Treating Isolated Systolic Hypertension
Somes, G. W., Pahor, M., Shorr, R. I., Cushman, W. C., & Applegate, W. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.17.2004 · Cited by 352
Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events
McEvoy, J. W., Chen, Y., Rawlings, A., Hoogeveen, R. C., Ballantyne, C. M., Blumenthal, R. S., Coresh, J., & Selvin, E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.754 · Cited by 350
Arterial stiffness in diabetes mellitus
Prenner, S. B., & Chirinos, J. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.023 · Cited by 313 · cited 1×
“This concern could be amplified in persons with T2DM because diabetes is not only an independent risk factor for micro- and macrovascular complications (12,13) but is also associated with increased arterial stiffness (14) and, consequently, a wide pulse pressure and low DBP.”
BackgroundAmerican Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s009 · Cited by 271
Stewart, I. M. G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91274-1 · Cited by 245 · cited 1×
“The concept of a J-shaped curve between on-treatment levels of DBP and CVD was first reported by Stewart (5) in 1979 and subsequently championed by others (6–11).”
BackgroundBeddhu, S., Chertow, G. M., Cheung, A. K., Cushman, W. C., Rahman, M., Greene, T., Wei, G., Campbell, R. C., Conroy, M., Freedman, B. I., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030848 · Cited by 175
Self-citationThe Myocardial Oxygen Supply:Demand Index Revisited
Hoffman, J. I. E., & Buckberg, G. D. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000285 · Cited by 166 · cited 2×
“Lowering SBP might preserve or improve myocardial O2 balance based on a decrease in myocardial O2 demand by lowering systolic pressure-time index (29) and a decrease in afterload with consequent regression of left ventricular hypertrophy and left ventricular mass, which compensates for the potential deleterious effect…”
BackgroundSim, J. J., Shi, J., Kovesdy, C. P., Kalantar-Zadeh, K., & Jacobsen, S. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.065 · Cited by 160
On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension
Fagard, R. H. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.17.1884 · Cited by 151
Beddhu, S., Chertow, G. M., Greene, T., Whelton, P. K., Ambrosius, W. T., Cheung, A. K., Cutler, J., Fine, L., Boucher, R., Wei, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009326 · Cited by 117 · cited 1×
“However, a recent analysis of the ACCORD BP data showed evidence of interaction between the intensive SBPand intensive glycemic control interventions (3).”
BackgroundSelf-citationAdamsson Eryd, S., Gudbjörnsdottir, S., Manhem, K., Rosengren, A., Svensson, A.-M., Miftaraj, M., Franzén, S., & Björck, S. (2016) · BMJ · doi:10.1136/bmj.i4070 · Cited by 75
(2017) · Diabetes Care · doi:10.2337/dc17-er07a · Cited by 67
Rönnback, M., Isomaa, B., Fagerudd, J. A., Forsblom, C. M., Groop, P., Tuomilehto, J., & Groop, L. (2005) · Hypertension · doi:10.1161/01.hyp.0000199667.30253.b7 · Cited by 54
Diastolic Pressure in Type 2 Diabetes
Osher, E., & Stern, N. (2008) · Diabetes Care · doi:10.2337/dc08-s262 · Cited by 20 · cited 2×
“For example, in 257 patients with T2DM in a clinical practice setting, titration of SBP to a goal of,130 mmHg achieved the target SBP in a third of the cohort, but in 57% of the patients, the attained DBP was#70 mmHg (15).”
Background
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
“However, in ACCORD BP, it was found that intensive blood pressure lowering decreased the risk of cardiovascular events irrespective of baseline diastolic blood pressure in patients who also received standard glycemic control (43).”
BackgroundJoseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Metadata
- Authors
- Ilkun, O. L., Greene, T., Cheung, A. K., Whelton, P. K., Wei, G., Boucher, R. E., Ambrosius, W., Chertow, G. M., & Beddhu, S.
- Affiliations
- University of Utah (US)
- Tulane University (US)
- Wake Forest University Health Sciences (US)
- Stanford Medicine (US)
- Corresponding author
- Beddhu, Srinivasan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-05-04
- Volume
- 43
- Issue
- 8
- Pages
- 1878-1884
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7372050
- OpenAlex
- W3021187935
- Cited by
- 46
- References
- 31
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 8 · 2023: 7 · 2022: 13 · 2021: 5 · 2020: 4
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R21-HL-145494)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK-091437)
- U.S. Public Health Service (UL1-RR-025764, C06-RR-11234)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, diastolic blood pressure, intensive blood pressure lowering, systolic blood pressure, cardiovascular outcomes, all-cause mortality, glycemic control, HbA1c, effect modification, baseline blood pressure
- MeSH terms
- Aged, Antihypertensive Agents, Blood Glucose, Blood Pressure, Blood Pressure Determination, Cause of Death, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diastole, Female, Humans, Hypertension, Male, Middle Aged, Mortality, Systole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.